The number of confirmed Rifampicin resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in France shows a consistent year-on-year increase from 2024 to 2028. The forecasted figures indicate a gradual upward trend with a percentage increase approximately around 2-3% annually across the forecasted span. This steady rise suggests progressive challenges in combating RR-/MDR-TB in the region.
Future trends to watch for include the potential impact of new medical interventions and policy implementations, population health initiatives, and shifts in funding towards TB control measures. Monitoring the development of antibiotic resistance is critical as it may affect future projections.
